Compounds > olmesartan
Page last updated: 2024-09-04

olmesartan and erythromycin

olmesartan has been researched along with erythromycin in 5 studies

Compound Research Comparison

Studies
(olmesartan)		Trials
(olmesartan)		Recent Studies (post-2010)
(olmesartan)		Studies
(erythromycin)		Trials
(erythromycin)		Recent Studies (post-2010) (erythromycin)
84118555414,5241,1381,926

Protein Interaction Comparison

ProteinTaxonomyolmesartan (IC50)erythromycin (IC50)
30S ribosomal protein S6Escherichia coli K-121.156
30S ribosomal protein S7Escherichia coli K-121.156
50S ribosomal protein L15Escherichia coli K-121.156
Cytochrome P450 3A4Homo sapiens (human)1.045
50S ribosomal protein L10Escherichia coli K-121.156
50S ribosomal protein L11Escherichia coli K-121.156
50S ribosomal protein L7/L12Escherichia coli K-121.156
50S ribosomal protein L19Escherichia coli K-121.156
50S ribosomal protein L1Escherichia coli K-121.156
50S ribosomal protein L20Escherichia coli K-121.156
50S ribosomal protein L27Escherichia coli K-121.156
50S ribosomal protein L28Escherichia coli K-121.156
50S ribosomal protein L29Escherichia coli K-121.156
50S ribosomal protein L31Escherichia coli K-121.156
50S ribosomal protein L31 type BEscherichia coli K-121.156
50S ribosomal protein L32Escherichia coli K-121.156
50S ribosomal protein L33Escherichia coli K-121.156
50S ribosomal protein L34Escherichia coli K-121.156
50S ribosomal protein L35Escherichia coli K-121.156
50S ribosomal protein L36Escherichia coli K-121.156
30S ribosomal protein S10Escherichia coli K-121.156
30S ribosomal protein S11Escherichia coli K-121.156
30S ribosomal protein S12Escherichia coli K-121.156
30S ribosomal protein S13Escherichia coli K-121.156
30S ribosomal protein S16Escherichia coli K-121.156
30S ribosomal protein S18Escherichia coli K-121.156
30S ribosomal protein S19Escherichia coli K-121.156
30S ribosomal protein S20Escherichia coli K-121.156
30S ribosomal protein S2Escherichia coli K-121.156
30S ribosomal protein S3Escherichia coli K-121.156
30S ribosomal protein S4Escherichia coli K-121.156
30S ribosomal protein S5Escherichia coli K-121.156
30S ribosomal protein S8Escherichia coli K-121.156
30S ribosomal protein S9Escherichia coli K-121.156
50S ribosomal protein L13Escherichia coli K-121.156
50S ribosomal protein L14Escherichia coli K-121.156
50S ribosomal protein L16Escherichia coli K-121.156
50S ribosomal protein L23Escherichia coli K-121.156
30S ribosomal protein S15Escherichia coli K-121.156
50S ribosomal protein L17Escherichia coli K-121.156
50S ribosomal protein L21Escherichia coli K-121.156
50S ribosomal protein L30Escherichia coli K-121.156
50S ribosomal protein L6Escherichia coli K-121.156
30S ribosomal protein S14Escherichia coli K-121.156
30S ribosomal protein S17Escherichia coli K-121.156
30S ribosomal protein S1Escherichia coli K-121.156
50S ribosomal protein L18Escherichia coli K-121.156
50S ribosomal protein L2Escherichia coli K-121.156
50S ribosomal protein L3Escherichia coli K-121.156
50S ribosomal protein L24Escherichia coli K-121.156
50S ribosomal protein L4Escherichia coli K-121.156
50S ribosomal protein L22Escherichia coli K-121.156
50S ribosomal protein L5Escherichia coli K-121.156
30S ribosomal protein S21Escherichia coli K-121.156
50S ribosomal protein L25Escherichia coli K-121.156
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.039
50S ribosomal protein L36 2Escherichia coli K-121.156

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Ekins, S; Williams, AJ; Xu, JJ1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ1

Other Studies

5 other study(ies) available for olmesartan and erythromycin

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7

    Topics: Glutathione; Pharmacology; Sulfur Radioisotopes

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:1

    Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity

2013